Biodesix downgraded to Market Perform from Outperform at William Blair

William Blair downgraded Biodesix (BDSX) to Market Perform from Outperform. The company lowered its full-year revenue guidance by 12% at the midpoint to reflect slower salesforce rep hiring and slightly higher rep attrition than expected, the analyst tells investors in a research note. The firm believes the Q1 update puts the stock in “show me status” until likely the latter part of 2025 or early 2026. The shares “may have a ceiling on them” even at what is a “very discounted valuation,” contends William Blair.